Loading
Beam Therapeutics Inc. Stock: price and insider trades · United States
Insider Decl.
465
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€118M
249 ops. · all time
Who traded when
BuySaleJohn M. Evans18 sales
Christine Bellon10 sales
Bethany J. Cavanagh8 sales
Amy Simon7 sales
FMR LLC4 sales
Giuseppe Ciaramella4 sales
+1 other insider
Analyst consensus: bullish or bearish?
Analysts rate Beam Therapeutics Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$52.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,176 of 26,284 companies
14.4
score / 100
Value18
Quality11
FCF yld-14%
Earn yld-3.1%
EV/EBITDA·
ROE-8.2%
Gross mgn·
Net mgn-57%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$24.93
Analyst consensus
13 analystsStrong buy
US$26.00Target US$52.15(+109%)US$80.00
Income statement
RevenueUS$139.7M
EBITDA-US$361.4M-259% margin
Net income-US$80M-55.4% margin
Valuation
PER (forward)-5.3x
P/Book2.3x
Beta2.20
Balance sheet & cash
Market capUS$2.6B
Total debtUS$154.1M
Free Cash Flow-US$360M
Debt / Equity23%
Profitability & ownership
ROE-8.2%
ROA-17.0%
% insiders1.2%
% institutions107.9%
Last declaration on 16 October 2026
Declarations465 total
25,000 shares@ US$23.98380.025% mcap20.7% of flowCommonSEC144:0001950047-26-010282
25,000 shares@ US$1.030.0010% mcap0.2% of flowCommon StockSEC:0001193125-26-424421:0
25,000 shares@ US$23.5660.023% mcap4.4% of flowCommon StockSEC:0001193125-26-424421:1
25,000 shares@ US$1.030.0010% mcap0.2% of flowCommon StockSEC:0001193125-26-424421:2
25,000 shares@ US$23.98380.024% mcap4.5% of flowCommon StockSEC:0001193125-26-424421:3
25,000 shares@ US$23.5660.023% mcap25.6% of flowCommonSEC144:0001950047-26-010253
187 shares@ US$24.410.0002% mcap0.6% of flowCommon StockSEC:0001193125-26-412236:0
123,407 shares0Common StockSEC:0001193125-26-402814:0
16,667 shares@ US$25.74170.017% mcap34.0% of flowCommon StockSEC:0001193125-26-323640:0
16,677 shares@ US$25.74170.017% mcap100.0% of flowCommonSEC144:0001950047-26-007314
373 shares@ US$34.731.0% of flowCommon StockSEC:0001193125-26-294478:0
18,663 sharesCommon StockSEC:0001193125-26-292526:0
6,337 sharesCommon StockSEC:0001193125-26-292526:1
13,421 shares@ US$35.13363.1% of flowCommon StockSEC:0001193125-26-292526:2
25,000 sharesCommon StockSEC:0001193125-26-292526:4
11,579 shares@ US$35.91192.7% of flowCommon StockSEC:0001193125-26-292526:3
23,100 shares@ US$34.26335.2% of flowCommon StockSEC:0001193125-26-292526:5
1,900 shares@ US$34.84370.4% of flowCommon StockSEC:0001193125-26-292526:6
25,000 shares@ US$34.30740.034% mcap49.2% of flowCommonSEC144:0001950047-26-006639
25,000 shares@ US$35.49410.035% mcap50.8% of flowCommonSEC144:0001950047-26-006578
33,372 shares@ US$35.1210.6% of flowCommon StockSEC:0001193125-26-288078:0
251,488 shares@ US$35.2680.2% of flowCommon StockSEC:0001193125-26-288078:1
6,505 sharesCommon StockSEC:0001193125-26-277509:0
29,000 sharesCommon StockSEC:0001193125-26-277509:1
5,956 shares@ US$24.5810.5% of flowCommon StockSEC:0001193125-26-144067:0
25 of 465 declarations
About Beam Therapeutics Inc.
No purchase appears at Beam Therapeutics Inc., a US healthcare and pharma company valued at USD 2.6 billion. Open-market activity is 249 sales worth EUR 118,035,708 (median EUR 172,335), plus 66 option exercises, 31 grants and 119 filings of another kind. The largest sale is FMR LLC's: EUR 24,339,865 on February 14, 2024, then EUR 7,804,701 on June 26, 2026. Giuseppe Ciaramella (President and CSO) sold EUR 4,471,261 on July 21, 2023.
John M. Evans (CEO) signs the most filings, 141, 105 of them sales, ahead of Giuseppe Ciaramella (President, 77, with 43 sales), FMR LLC (10% Owner, 58, with 15 sales) and Terry-Ann Burrell (Chief Financial Officer, 39, with 25 sales). ARCH Venture Partners IX, LLC (10% Owner) has 29, with no purchase or sale.
Read moreShow less
The 465 filings were published between February 11, 2020 and October 16, 2026. Yearly volume peaks at 200 in 2021. The last twelve months hold 58 filings, 32 of them sales and no purchase. Insiders hold 1.2% of the capital.
